profit from every $100 of sales.
$0$100
AEON Biopharma
$0.17-4.41% today
-81.6% in 1 year
1-year low $0.161-year high $1.36
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What AEON Biopharma sold, what it kept, and what it did with the cash.
Sales went from $0 in 2021 to $0 in 2025, with -$39.2 million of profit last year.
SalesProfit
AEON Biopharma vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| AEON Biopharma | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads AEON Biopharma's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2021 | 2022 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -37 | -48 | -28 | -16 | |
| -37 | -48 | -28 | -16 | |
| -56 | -53 | 42 | -39 | |
| -182.12 | -172.03 | 72.93 | -3.95 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2021 | 2022 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | – | 11 | 3 | 6 |
| Cash | – | 10 | 0 | 3 |
| Total debt | – | 132 | 13 | 36 |
| Total liabilities | – | 281 | 32 | 61 |
| – | -288 | -29 | -55 | |
| – | 0 | 1 | 10 | |
| – | – | – | – | |
| – | 18.3% | -147.0% | 71.3% |
Cash flow
| In millions of USD | 2021 | 2022 | 2024 | 2025 |
|---|---|---|---|---|
| -28 | -36 | -20 | -17 | |
| 0 | 0 | – | 0 | |
| -29 | -36 | -20 | -17 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 5 | 6 | 6 | 5 |
Valuation
- –
- –
- –
- -0.2×
- –
- –
- –
- -141.2%
- -320.0%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- 1,557.8%
- 51.5%
- 153.7%
- -705.4%
- 1,264.2%
- –
Growth
- –
- –
- +14.7%
- –
- +54.2%
Financial health
- -1.9×
- -0.65
- 642.9%
- –
- 0.49
- 0.49
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 21%of 888
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | -0.44 | -0.44 | +0.0% |
| Mar 30, 2026 | -3.72 | -0.21 | −1,714.6% |
| Nov 14, 2025 | -0.39 | -0.43 | +9.3% |
| Aug 12, 2025 | -0.60 | – | – |
| May 14, 2025 | -0.09 | -13.67 | +99.3% |
| Mar 24, 2025 | 3.75 | -12.95 | +129.0% |
| Nov 13, 2024 | -11.51 | -11.51 | +0.0% |
| Aug 12, 2024 | -11.51 | -13.67 | +15.8% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/4Passes 0 of 4. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
42No pass
Benjamin Graham
–Not enough data
Philip Fisher
42No pass
Peter Lynch
–Not enough data
Joel Greenblatt
–Not enough data
Charlie Munger
50No pass
Terry Smith
45No pass
Questions about AEON Biopharma
Is AEON Biopharma a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 4 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the AEON Biopharma AI analysis
What does AEON Biopharma do?
AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. It also develops 900 kDabotulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. It is in Biotechnology.
Does AEON Biopharma pay a dividend?
No. AEON Biopharma does not pay a dividend at the moment.
Is AEON Biopharma stock halal?
No. AEON Biopharma does not pass our halal screen: its debt is 292% of its market value, at or above the 33% limit. How we check
How has AEON Biopharma stock done over the past year?
Down 81.6% over the past twelve months, to $0.17. It traded between $0.16 and $1.36 and is 87.4% below its high.
Who are AEON Biopharma's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with AEON Biopharma's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.